

# ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it

Christian Rolfo<sup>1\*</sup>, Francesco Passiglia<sup>1,2\*</sup>, Marta Castiglia<sup>2,3</sup>, Luis E. Raez<sup>4</sup>, Paul Germonpre<sup>5</sup>, Ignacio Gil-Bazo<sup>6</sup>, Karen Zwaenepoel<sup>3</sup>, Annemieke De Wilde<sup>3</sup>, Giuseppe Bronte<sup>2</sup>, Antonio Russo<sup>2</sup>, Jan P. Van Meerbeeck<sup>7</sup>, Paul Van Schil<sup>8</sup>, Patrick Pauwels<sup>3</sup>

<sup>1</sup>Phase I-Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium; <sup>2</sup>Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; <sup>3</sup>Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Edegem, Belgium; <sup>4</sup>Memorial Cancer Institute, Memorial Health Care System, Florida International University, Miami, FL, USA; <sup>5</sup>Thoracic Oncology Unit, Integrated Cancer Centre, AZ Maria Middelaers, Gent, Belgium; <sup>6</sup>Lung Cancer Unit, Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain; <sup>7</sup>Thoracic Oncology, Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium; <sup>8</sup>Thoracic Surgery Department, Antwerp University Hospital, Edegem, Belgium

\*These authors contributed equally to this work.

Correspondence to: Prof. Dr. Christian Rolfo, MD, PhD. Head of Unit, Phase I-Early Clinical Trials, Oncology Department, University Hospital Antwerp UZA, Wilrijkstraat 10, 2650 Edegem, Belgium. Email: christian.rolfo@uza.be.

**Abstract:** The last few decades have witnessed a silent revolution in the war against NSCLC, thanks to the discovery of “oncogenic drivers” and the subsequent development of targeted therapies. The discovery of the EML4-ALK fusion gene in a subgroup of patients with NSCLC and the subsequent clinical development of crizotinib has been an amazing success story in lung cancer translational-research, and its accelerated approval [only 4 years from the discovery of ALK rearrangement in NSCLC to the approval by the Food and Drug Administration (FDA)] marked the beginning of the new decade of targeted therapy. However, common to all targeted therapies, despite an initial benefit, patients inevitably experience tumor progression, due to the development of resistance. Several molecular mechanisms are responsible for acquired resistance, such as secondary mutations of ALK kinase domain or amplification of *ALK* fusion gene, or the activation of other oncogenic drivers, which may cause resistance independently of ALK genetic alterations. Pre-clinical data and early clinical trials showed the promising efficacy of a new class of ALK-inhibitors in overcoming acquired resistance. The inhibition of the molecular chaperone, HSP90, represents another promising strategy to overcome crizotinib resistance in ALK-rearranged NSCLC. Several molecules are currently under investigation in order to establish their specific role in the treatment of ALK-rearranged NSCLC.

**Keywords:** ALK rearrangements; NSCLC; ALK inhibitors; resistance

Submitted Feb 20, 2014. Accepted for publication Mar 06, 2014.

doi: 10.3978/j.issn.2218-6751.2014.03.01

View this article at: <http://dx.doi.org/10.3978/j.issn.2218-6751.2014.03.01>

## Introduction

In the last few decades several advances have been made in translational research, thanks to the discovery of key-oncogene alterations, responsible for cancer cell proliferation and survival, and the subsequent advent of targeted drugs capable to inactivate them. This knowledge led to a gradual shift of lung cancer subtyping from a histological

to a molecular basis. In fact, even if the histological subtype is considered in the choice between the different chemotherapies, the tumor molecular profile is crucial in order to personalize new targeted treatments. This was first demonstrated in 2004, with the discovery of sensitive epidermal growth factor receptor (EGFR) mutations and subsequent correlation with clinical responses to EGFR

tyrosine-kinase-inhibitors (TKIs) (1,2), leading to the subsequent approval of gefitinib, erlotinib, and recently afatinib, as first line treatment in this subset of NSCLC patients (3). The discovery of the EML4-ALK fusion gene in a subgroup of patients with NSCLC (4), was followed by the development of a new class of agents, the ALK inhibitors, which dramatically improved the clinical outcome of those patients. This review will briefly discuss the biology of EML4-ALK gene and the clinical development of crizotinib in NSCLC, focusing on emerging mechanisms of acquired resistance and new treatment strategies to overcome it.

## ALK-translocation in NSCLC


### *EML4-ALK chromosome rearrangement*

Transforming rearrangement of the *ALK* gene was first reported in anaplastic large-cell lymphoma in 1994 (5), while in 2007 Soda *et al.* identified the *ALK* gene-rearrangement with EML4 in NSCLC (4). This rearrangement led to a fusion between the N-terminal portion of the *EML4* protein with the intracellular region of the ALK receptor, resulting in a constitutive, ligand-independent activation of the tyrosine-kinase-domain of the rearranged ALK-receptor and downstream signaling pathways, such as Ras/MAPK, PI3K/Akt, and JACK/STAT3 pathways, responsible for both, tumor cell proliferation and survival (6). *EML4-ALK* fusion gene is a potent oncogenic driver, reported in about 3-7% of all NSCLC patients (7). Other fusion partners for *ALK* have been discovered in NSCLC, (such as TFG and KIF5B) (8-10), and multiple *EML4-ALK* variants have been identified, (such as E13;A20, and E6a/b;A20) (11), but their clinical significance still remains unknown. *In vitro* studies show some differences in sensitivity among the different variants to ALK-inhibition (12), but no correlation has been yet observed in this clinical setting. *ALK* rearrangement is a relatively rare event in the unselected NSCLC population. Data obtained by different studies show that it occurs more frequently in adenocarcinomas, in light or never smokers, and younger patients, but was also found, at a much lower rate, in squamous or adeno-squamous carcinomas and in smokers (7,13). *ALK* rearrangements are not fully mutually exclusive with *EGFR* or *KRAS* mutations; several simultaneously occurring *EGFR* and *KRAS* mutations in *ALK*-positive patients have been recently reported (14,15). *ALK*-positive tumors seem to be associated with a worse survival and an increased risk of brain and liver

metastases (16), but an improved prognosis is observed in the context of treatment with ALK inhibitors (17). Several studies showed a lack of response to EGFR-TKIs (7,13,18). Finally, *ALK* rearrangements define a new molecular subtype of NSCLC that is exquisitely sensitive to a new class of tailored agents, the ALK inhibitors.

### *ALK-rearrangement detection*

Several techniques are currently under investigation in order to detect *ALK*-rearrangements in NSCLC, such as fluorescence *in situ* hybridization (FISH), immunohistochemistry (IHC), and reverse transcriptase PCR (RT-PCR), each showing advantages and limitations. Currently, FISH using break-apart probes is considered the gold standard, approved by the Food and Drug Administration (FDA) to identify ALK-rearranged NSCLC. It was tested and validated in clinical trials that have led to the approval of crizotinib, an ALK TKI, and it is used to screen patients to enter the ongoing trials with second-generation ALK inhibitors. According to the definition of this test, ALK-FISH is considered positive if a split in more than 15% tumor cells occurs and counting at least 60 cells (19). Despite many positive features, the *ALK* FISH test has also several disadvantages. It requires laboratories with an experienced operator, and it results expensive. IHC is an easier and cheaper method, generally available in local laboratories, based on the use of ALK-specific monoclonal antibody. Several studies showed a strong correlation between ALK-rearrangement positivity, as detected by FISH, and ALK protein overexpression, as detected by IHC (20-26). These findings suggest that IHC could be used for screening of *ALK* rearrangements prior to FISH, leading to the development of new diagnostic algorithms, which need to be validated in large scale concordance studies. Finally RT-PCR is the most sensitive method of detecting not only *ALK* rearrangements, but also of characterizing their variant types, and the abundance of *EML4-ALK* positive cells in NSCLC tumor tissues (27). It also has the advantage of requiring limited amount of material for analysis and is relatively easy to perform, but the development of this method as a diagnostic tool has several limitations (28). The optimal diagnostic strategy for ALK rearrangement remains to date a matter of debate, but FISH may be still considered the gold standard to consider the patient to crizotinib or other ALK inhibitors. A properly validated immunohistochemical method could be considered as a screening test (*Figure 1*).



**Figure 1** ALK translocation FISH break-apart positive in a NSCLC patient.

### Clinical development of crizotinib


#### Clinical efficacy

Crizotinib is an oral, selective, ATP-competitive, small molecule, originally developed as c-MET inhibitor, approved for the treatment of ALK+, pre-treated NSCLC patients (3). In pre-clinical studies, it showed a great activity against c-MET-positive and ALK-positive cell lines (29), on the basis of which, a first in human, phase I, dose-escalation trial, evaluated crizotinib as an oral single agent in 37 patients with advanced solid tumors, identifying 250 mg twice daily as the recommended dose (30). There were two patients with NSCLC harboring *EML4-ALK* rearrangement treated with crizotinib who showed dramatic improvement in their symptoms during the dose escalation phase. That observation led to a large prospective screening of NSCLC patients and recruitment of those with ALK-positive NSCLC into an expanded molecular cohort at the maximum tolerated dose (MTD) of 250 mg twice daily (31). The updated results, reported by Camidge *et al.*, including 149 previously treated and untreated, ALK+ NSCLC patients, showed three complete response (CR) and 84 partial response (PR), for an overall response rate (ORR) of 61% with a median duration of response of 49.1 weeks, and a median PFS of 9.7 months (95% CI, 7.7-12.8) (32). At the time of presentation, overall survival (OS) data were not mature. Noteworthy, 39 patients continued to receive crizotinib for more than 2 weeks after progression due to a perceived clinical benefit from the physician. The phase II trial (PROFILE1005) confirmed these striking results on 261 ALK+ pre-treated NSCLC patients. The ORR was 59.8%, with a median duration of response of 45.6 weeks, and a median PFS of 8.1 months (95% CI, 6.8-9.7) (33).

On the basis of these impressive results, the FDA approved the use of crizotinib in October 2011, for the treatment of ALK+ advanced NSCLC. Two phase III trials have compared crizotinib to chemotherapy in a selected population. First, the PROFILE1007 trial compared crizotinib to chemotherapy (docetaxel or pemetrexed), in ALK+ NSCLC patients after one previous platinum-based chemotherapy regimen (34). The study met its primary endpoint, with a median PFS of 7.7 months for patients treated with crizotinib *vs.* 3.0 months for those treated with chemotherapy (HR: 0.49; 95% CI, 0.37-0.64;  $P < 0.0001$ ). The ORR was also significantly higher for the crizotinib arm compared to the chemotherapy group (65% *vs.* 20%;  $P < 0.0001$ ). Another interesting feature emerging from the PROFILE1007 trial is a strong correlation between ALK-rearrangement and pemetrexed efficacy. In fact, better results were reported in patients treated with pemetrexed, compared to those treated with docetaxel, both in terms of RR (29.3% *vs.* 6.9%) and PFS (4.2 *vs.* 2.6 months), respectively. This could be related to the lower concentration of thymidylate synthase (TS), the main target of pemetrexed, in ALK+ tumors (35), but this assumption needs further validation in prospective, randomized studies. Finally, the ongoing open label phase III clinical trial PROFILE1014 trial is comparing crizotinib against a platinum-based doublet (cisplatin or carboplatin plus pemetrexed) in previously untreated, ALK-positive, stage IIIB/IV NSCLC patients. Waiting for the results in first line-setting, the European Society of Medical Oncology (ESMO) guidelines recommend crizotinib as the treatment of choice for ALK+ NSCLC patients only after progression to a first-line chemotherapy regimen (3). The analysis of data from all phases I-III studies regarding the toxic effects of crizotinib shows a good tolerability profile. The most frequent treatment-related adverse effects (AEs) were visual disorders (grades 1,2). Elevated amino transferase, lymphopenia, neutropenia, and pneumonitis were the most common treatment-related grade 3 or 4 AEs, observed in 7-15%, 11.4%, 5.2%, and 1-5% of patients, respectively. Finally, about 69% of patients experienced at least one episode of sinus bradycardia (HR  $\leq 60$  bpm). Patients treated with crizotinib reported greater improvement in lung cancer symptoms and greater improvement in global quality of life when compared with chemotherapy (34) (Figure 2 and Table 1).

#### Crizotinib: also a ROS1 and c-MET inhibitor

Even though crizotinib has been approved for the treatment of ALK positive NSCLC, it has shown activity



**Figure 2** A computerized tomography (CT) scan of the thorax showing an objective response in an ALK-rearranged lung tumor of a patient treated with crizotinib. (A) 49-year-old women, PS 4, with advanced, ALK-traslocated, NSCLC: baseline CT-scan; (B) 49-year-old women, PS 4, with advanced, ALK-traslocated, NSCLC: CT-scan two weeks after treatment initiation with crizotinib.

Study	Phase	Patients included	ORR (%)	PFS (months)	Author
PROFILE 1001	Phase I	N: 149 pt (NSCLC; ALK+)	60.8 (95% CI, 52.3-68.9)	9.7 (95% CI, 7.7-12.8)	Camidge 2012 (32)
PROFILE 1005	Phase II	N: 261 pt (NSCLC; ALK+)	60 (95% CI, 53.6-65.9)	8.1 (95% CI, 6.8-9.7)	Kim 2012 (33)
PROFILE 1007	Phase III (CZT vs. P/D)	N: 346 pt (NSCLC; ALK+)	65 vs. 19.5 P<0.0001	7.7 vs. 3.0 P<0.0001	Shaw 2013 (34)
PROFILE 1014	Phase III (CZT vs. C + P)	(NSCLC; ALK+)	Ongoing	Ongoing	(NCT01639001)

ORR, objective response rate; PFS, progression free survival; CZT, crizotinib; P, pemetrexed; D, docetaxel; C, cisplatin or carboplatin.

also in other subgroup of NSCLC patients whose tumors presented *ROS1* gene rearrangements. *ROS1* is a receptor tyrosine kinase of the insulin receptor superfamily, and it is most closely related to ALK. Multiple *ROS1* fusion partners have been identified in NSCLC (*TPM3*, *SDC4*, *SLC34A2*, *CD74*, *EZR*, *LRIG3*, and *FIG*), resulting in a ligand-independent, constitutive activation of *ROS1* fusion kinase responsible for both, cancer cell proliferation and survival (36,37). *ROS1* rearrangements are reported in about 1-2% of the whole NSCLC population (38), mostly

in young people, never smokers, with an adenocarcinoma histology subtype (39), and seems to be mutually exclusive with other common mutations, like *EGFR*, *K-RAS* and *ALK*. Although the amino-acid sequence of *ROS1* does not completely correspond to ALK in the kinase domain, *ROS1* positive tumors showed *in vitro* sensitivity to several ALK-Inhibitors (40). On the basis of these encouraging results in preclinical studies (39), an expansion cohort of the initial crizotinib phase I trial, included 23 patients with advanced NSCLC harboring *ROS1* rearrangements, reporting an



impressive ORR of 50% (10/20), with 9 PRs and 1 CR (41). Recruitment is still ongoing, but early results suggest that crizotinib could be also considered the standard of care for another subgroup of molecularly selected NSCLC patients. Finally, crizotinib could also represent an efficacy treatment for NSCLC with *c-MET* (mesenchymal-epithelial transition factor) amplifications, which have been reported to be oncogenic drivers in about 4-11% of patients (42,43), and are implicated in about 22% of the cases of acquired resistance to EGFR TKI (44). Although it was recently approved by the FDA as an ALK-inhibitor, it was synthesized primarily as a Met inhibitor. A recent case report described a rapid and durable response to crizotinib in a NSCLC patient carrying a *de novo MET* amplification and lacking an *ALK* rearrangement (43). Furthermore, several ongoing trials are investigating the combination of crizotinib with therapies targeting EGFR (erlotinib, NCT00965731; dacomitinib, PF-00299804, NCT01121575) to overcome EGFR-TKI acquired resistance, due to *MET* amplification.

### Mechanisms of crizotinib resistance

Despite of a dramatic initial activity of crizotinib in molecularly defined, *ALK*-rearranged, NSCLC population, common to other targeted therapies used in NSCLC, such as EGFR-TKIs, acquired resistance to TKIs inevitably develops during the first year of treatment. In the clinic, relapses during crizotinib treatment commonly involve the central nervous system (CNS). The reasons for crizotinib failure at CNS are actually unknown, and data available from clinical studies are controversial. In fact, in the phase II PROFILE1005 study (33), only 2 out of 18 enrolled patients with brain metastasis developed CNS progression under crizotinib treatment, while in another study (45), 13 out of 28 *ALK*-positive patients (46%) treated developed brain metastasis. Whether and how acquired resistance alterations may contribute to resistance in the CNS is actually unknown. However, extremely lower crizotinib concentration in the cerebrospinal fluid (CSF) compared to the plasma, was recently reported in one patient with focal CNS progression during crizotinib treatment (46), suggesting a possible pharmacokinetic mechanism, like inadequate drug exposure in a sanctuary site, as possible cause of the high rate of CNS relapse in *ALK*-positive patients. We may distinguish between “intrinsic TKI resistance”, which usually occurs earlier, especially in “fast progressive” patients, and, “acquired TKI resistance”, which more frequently occurs, within 8-10 months from crizotinib

initiation (34). However, some cases showing more than 24 months of clinical benefit have been reported (32).

Recently, *in vitro* studies have shown a different sensitivity to ALK-inhibition among the different variants of the *ALK*-fusion gene (12), suggesting a possible explanation for intrinsic resistance to crizotinib, but this correlation was not confirmed in a subgroup analysis from a phase I trial of crizotinib (31). Mechanisms of acquired resistance to crizotinib may be divided into two categories. The first one includes additional genetic alterations in the target, such as secondary mutations of the *ALK* Kinase domain or amplification of the *ALK* fusion gene, which preserve and facilitate the *ALK* signaling pathway activity (47,48). Regarding the secondary mutations, the most common and well characterized, is the L1196M mutation (49), consisting of a substitution of methionine for leucine in the “gatekeeper” residue, promoting formation of the active conformation of the protein and leading to an increased protein kinase activity (50). Common to the others gatekeeper mutations, like T790M in EGFR (51), the L1196M mutation interferes with the inhibition of the kinase activity by the targeted agent, promoting enzyme activation and not preventing the access of the drug into the hydrophobic binding pocket. Additional resistance mutations include: G1269A, C1156Y, L1152R, G1202R, S1206Y, 1151Tins, and recently F1174C and D1203N. In *in vitro* experiments, all these secondary mutations reduced crizotinib binding and/or increased affinity for ATP, conferring different sensitivity to ALK-Inhibitors. In particular, G1269A and 1151Tins mutations increase the *ALK* kinase affinity for the ATP (52). G1202R and S1206Y mutations induce conformational changes, causing hindrance of crizotinib binding. Finally, C1156Y mutations lead to specific conformational changes in the binding site of the drug, decreasing the affinity of crizotinib, while L1152R mutations reduce crizotinib activity interfering with the downstream signaling pathway phosphorylation (53,54). *ALK* fusion gene amplification, alone or in combination with secondary mutations, has also been identified as a sufficient cause for developing crizotinib resistance in cell lines experiments, and subsequent studies have confirmed *ALK* fusion gene amplification in resistant clinical specimens (48,55). It was supposed that normal doses of crizotinib could not inhibit a fraction of *ALK* fusion proteins, and that increased expression may allow sufficient downstream signaling for tumor cell survival. These so-called “*ALK* dominant mechanisms” are involved in about 30% of acquired resistance to crizotinib. The

**Table 2** New drugs targeting EML4-ALK in NSCLC patients

Drug	MTD	DLTs	Patients [N]	ORR (%)	Author
AP26113	120 mg daily	↑ALT, dyspnea, and hypoxia	CZT-resistant [16]	76	Camidge 2013 (57)
LDK378	750 mg daily	Diarrhea, nausea-vomiting dehydration	CZT-resistant [26]	81	Shaw 2012 (58)
CH5424802	300 mg BID	Not determined	CZT-naïve [49]	85.7	Nishio 2012 (59)
	900 mg BID		CZT-resistant [37]	48	Gadgeel 2013 (60)
IPI504	N.A	Not determined	CZT-naïve [3]	66.6	Sequist 2010 (61)
Ganetespib	N.A	Not determined	CZT-naïve	50	El-Hariry 2012 (62)
AUY922	70 mg/m <sup>2</sup> weekly	Anorexia, diarrhea, dark vision, asthenia, fatigue	CZT naïve	50	Felip 2012 (63)

CZT, crizotinib; N.A, not available.

second category of mechanisms includes activation of other oncogenic drivers, which may cause resistance through reactivation of downstream signaling pathways via bypass tracts, independently of ALK genetic alterations.

Recently, in 3 out of 11 *ALK*+ specimens, EGFR phosphorylation and K-RAS mutation were found in the post crizotinib biopsy, and *c-KIT* amplification was identified in 2 of 13 resistant specimens (47,48), suggesting that under crizotinib treatment pressure, pre-existent oncogenic drivers present in the same cells or in other clones, may emerge leading to the development of the resistance. Furthermore, with regards to *c-Kit* activation, *in vitro* studies showed that it is completely dependent on the concentration of stroma derived stem cell factor (SCF) in the tumor specimen. In fact, the crizotinib plus imatinib combination may lead to a decrease in c-Kit+ cells proliferation only in presence of SCF, suggesting also the involvement of the microenvironment in the development of crizotinib resistance (47). Therefore, *K-RAS* mutations, *KIT* amplification and increased EGFR autophosphorylation and mutations, represent the so-called “ALK non-dominant mechanisms” involved in the development of the acquired resistance to crizotinib. Occasionally, multiple different resistance mechanisms may be found in the same tumor of the same patient, suggesting the need of combination therapies, such as ALK inhibitors, with therapies targeting EGFR, erlotinib or dacomitinib, to optimize the patients’ outcomes (56). Finally, the specific mechanism of acquired resistance development during crizotinib treatment remain still unknown in about 20% of patients, and loss of the *ALK* fusion oncogene has been supposed as an additional potential mechanism of resistance (47,48). The dynamic nature of the tumor and the higher heterogeneity of resistance mechanisms, underscore the need of a re-biopsy at each new phase of treatment, to

better understand the specific molecular profile of each patient and personalize the treatment. The development of not invasive tools for monitoring resistance, such as mutational analysis of circulating free DNA or circulating tumor cells, will be crucial in the near future.

### Emerging strategies to overcome resistance

Next-generation ALK inhibitors (e.g., AP26113, LDK378, CH5424802) and HSP90 inhibitors [e.g., STA-9090 (ganetespib), IPI-504, and AUY922] represent two different, promising, strategies to overcome the “ALK-dominant” resistance to crizotinib, both under investigation in early ongoing phase I/II clinical trials (*Table 2*). Next generation ALK inhibitors potently inhibit the ALK kinase and have activity against many of the resistance mutations *in vitro* and *in vivo*, also in the CNS. Although not ALK-specific, HSP90 inhibitors may overcome crizotinib resistance by decreasing proper folding of the oncogenic proteins, including ALK fusion protein. In the case of the activation of other oncogenic drivers, such as upregulation of *EGFR* and *c-KIT*, dual inhibition of ALK and these altered enzymes or the downstream effector pathways, such as PI3K/AKT/mTOR and MEK/ERK, represent potential therapeutic strategies. Finally, about 33% of patients enrolled in the PROFILE1007 trial who developed focal brain progression continuing on crizotinib treatment after progression in combination with local therapy. Median duration of crizotinib treatment beyond progression was 15.9 weeks, suggesting a new possible treatment strategy in this specific subset of patients (34). Recently, a case report by Matsuoka *et al.* (64), described a pronounced antitumor effect of crizotinib rechallenge in a Japanese woman with *ALK* rearranged NSCLC who initially responded to this drug but subsequently showed

tumor progression. Analogously to the T790M mutation in the EGFR gene, the temporary drug withdrawal could restore cell sensitivity to the TKI, through a reduction in the proportion of cells harboring the acquired resistant mutation (65), allowing the subsequent retreatment with the same TKI.

## New ALK-inhibitors

### LDK378

This compound is a novel, potent, and selective ALK-inhibitor also active against the C1156Y acquired mutation in xenograft models. It was synthesized based on the structure of TAE684, a previous ALK-inhibitor not suitable for clinical development, because of its potential to generate toxic reactive adducts. Extensive medicinal chemistry modifications were successfully undertaken, leading to the synthesis of novel derivatives that did not form reactive adducts and that potently inhibited ALK, like LDK378. Both in biochemical and cellular assays, LDK378 showed potent antiproliferative activity, with an IC<sub>50</sub> value of 2.2 nmol/L, lower than the IC<sub>50</sub> of crizotinib. It showed an excellent pharmacokinetics profile in animals, with an oral bioavailability of >50%, and also a good tolerability profile.

On the basis of encouraging pre-clinical data a phase I, first in human study was conducted in patients with ALK-positive advanced malignancies that were both treatment-naïve and also progressed on standard targeted therapy. The MTD was defined at 750 mg/daily and dose-limiting toxicities (DLT) included diarrhea, nausea-vomiting and dehydration. A total of 47 patients with NSCLC were evaluable for response; 51% of them achieved a PR. Interestingly, of the 26 patients with NSCLC who had progressed following crizotinib and were treated at dose of ≥400 mg/day, there were 21 (81%) responses (58). Another phase I trial exploring the MTD and/or recommended dose in Japanese patients with tumors harboring ALK alterations, mostly NSCLC (18/19) showed that the safety profile was tolerable and comparable to that of Western patients, with MTD: 750 mg. LDK378 exhibited antitumor activity not only in crizotinib naïve patients but also in resistant ALK+ NSCLC patients, with an ORR of 50%. PRs were observed in 7/9 (77.7%) crizotinib pretreated patients (66).

Considering the phase I promising results LDK378 received the breakthrough therapy designation by the FDA for the treatment of patients with ALK+ metastatic NSCLC who had progressed to crizotinib. Currently, two

confirmatory phase II studies of LDK378 in crizotinib-naïve (NCT01685060) and crizotinib-resistant ALK+ (NCT01685138) NSCLC patients are ongoing. In addition, two phase III trials comparing this novel agent with standard chemotherapy in ALK+ NSCLC untreated patients (NCT01828099) or after platinum and crizotinib failure (NCT01828112), are also recruiting patients.

### AP26113

This drug is a novel, synthetic, orally-active TKI, which potently inhibits mutant activated forms of *ALK*, *ROS*, and *EGFR* in cell lines, including the ALK-L1196M and EGFR-T790M mutations (67,68), but not native *EGFR*. *In vitro* studies showed a potent antiproliferative activity, with an IC<sub>50</sub> of 15-45 nmol/L, lower than crizotinib for the wild type and the L1196M mutant *ALK*. Preliminary data available from a phase I/II ongoing trial showed that AP26113 was well tolerated with preliminary antitumor activity in *ALK*-positive patients who had failed prior crizotinib. As of April 17<sup>th</sup> 2013, among 24 evaluable patients, 14 responded: 2/4 (50%) ALK+ crizotinib naïve patients, and 12/16 (76%) ALK+, crizotinib resistant patients. Furthermore, 4/5 patients with untreated or progressing CNS lesions, experienced objective responses, that are currently maintained. The most common AEs included fatigue (40%), nausea (36%) and diarrhea (33%), while the most common grade 3/4 AE was pneumonia (5%). DLT were observed in two patients (grade 3 ALT increase, grade 4 dyspnea and grade 3 hypoxia) (57). Therefore, the dose of 180 mg was determined for the phase II expansion study, which will include five cohorts: *ALK*-positive NSCLC patients who are naïve or resistant to prior ALK-targeted therapy; *EGFR* mutated NSCLC patients who are resistant to *EGFR* targeted therapy; other cancers with abnormalities in the *ALK* gene or other AP26113 targets (such as *ROS1*), and finally an *ALK*+ brain metastasis dedicated cohort. This study is currently recruiting patients (69).

### CH5424802

This compound is a highly potent (IC<sub>50</sub> =1.9 nmol/L), selective, oral ALK inhibitor. It binds to the ATP site of ALK, preventing the ALK autophosphorylation, showing antitumor activity against NSCLC cells expressing *EML4/ALK* fusion in preclinical studies, but also against mostly of the second site mutations of the ALK domain, notably the

L1196M gatekeeper mutation and C1156Y mutation (70). Preclinical studies in CNS implantation models also suggest a promising antitumor activity of CH5424802 against CNS lesions. A phase I/II trial has been recently presented using CH5424802 in *ALK*-positive, Japanese, NSCLC patients. In the phase I portion, dose was escalated using an accelerated titration scheme. During that phase, 15 patients were treated with CH5424802. When doses of 300 mg twice daily, the highest dose level defined in the protocol, were administered, MTD was not reached since a DLT was not determined. All patients (at all dose levels) achieved tumor regression and at dose levels of 240 mg twice daily or more under fasting conditions. All seven patients with measurable lesions achieved a PR (71). In the phase II portion of the trial, a total of 34 patients with no prior exposure to *ALK* inhibitor therapy were treated with CH5424802 at a 300 mg dose twice daily. The reported response rate in the first 15 evaluable patients was 73.3% with 1 CR and 10 PR. No treatment-related AEs led to dose reductions. Main treatment-related AEs among 34 patients were liver function test abnormalities, dysgeusia, rash, nausea and myalgia, most of them grade 1 except for neutropenia. Responses were seen in 3 patients with brain metastases (59). A phase II trial (NCT 01588028) is ongoing. Another phase I study of CH5424802 (900 mg), including 37 *ALK*+ NSCLC patients who have failed to crizotinib, showed preliminary efficacy and good tolerability profile also in this subset of patients, with PR in 48% and stable disease (SD) in 34%. The most common AEs were fatigue, CPK increase, myalgia, cough, ALT increase, peripheral edema and rash. Grade 3/4 AEs include GGT increase (n=3), neutrophil decrease (n=2), but no grade 3 nausea, vomiting, diarrhea or edema were reported (60). Furthermore, within 3-6 weeks after treatment initiation, CH5424802 dramatically shrank brain lesions previously progressed on crizotinib, suggesting a possible role in replacing or delaying the need of brain radiation in *ALK*-positive NSCLC patients (72).

### **HSP90-inhibitors**

The inhibition of the molecular chaperone, HSP90, represents a new promising strategy to overcome the “*ALK*-dominant” crizotinib resistance (due to secondary mutations or amplification) in *ALK*-rearranged NSCLC. The inhibition of HSP90 prevents from regulating the activation and stability of its client proteins, including oncogenic proteins such as *ALK*, facilitating their

proteasome mediated degradation (73). This degradation leads to a potent inhibition of downstream signaling pathways, the arrest of cell growth and the induction of apoptosis in cells carrying the *EML4-ALK* fusion (74). Some *in vitro* studies have shown that Hsp90 inhibitors are active against all types of acquired *ALK* mutations identified, particularly in the case of L1196M mutation, and also against *ALK* amplification (55). Furthermore, HSP90 inhibition led to a reduced expression of *EML4-ALK* in animal models (56). Several HSP-inhibitors have been developed and tested in the clinical setting. In fact, in those clinical trials usually including NSCLC patients with a heterogeneous molecular profile (*EGFR*-mutations, *KRAS*-mutations, *ALK*-rearrangements), promising results have been observed in the *ALK*-rearranged subgroup of patients. In a phase II study testing the HSP90 Inhibitor IPI-504, 2 out of 3 *ALK*+ NSCLC patients enrolled responded, with a median PFS of 7 months (61). This is probably related to the crucial role of HSP90 as a chaperone for *ALK* protein. In fact, preclinical studies showed high sensitivity of *EML4-ALK*+ NSCLC cells to the HSP90-inhibitor IPI-504 which induces tumor regression in a xenograft model, showing activity also against cells that have been selected for resistance to *ALK* kinase inhibitors (74). In a phase II clinical trial with another HSP90-Inhibitor, ganetespib, in monotherapy, a total of 99 NSCLC patients were included and divided according to their molecular profile into three cohorts: *EGFR*+, *KRAS*+, and *EGFR/KRAS* wild type. Among the wild type subgroup, only four responders have been reported, and all four patients have been subsequently found to be *ALK*+ (75). In another study, ganetespib showed an ORR of 50% in *ALK*+ crizotinib-naïve population (62). On the basis of these encouraging evidences, several clinical trials are currently exploring the activity of the HSP-inhibitor ganetespib, alone (NCT01562015), or in combination with crizotinib (NCT01579994) in *ALK*+ NSCLC. A phase II study with AUY922 was conducted in patients with previously treated advanced NSCLC, stratified by molecular status (*ALK*-positive, *EGFR*-mutant, *KRAS* mutant or wild-type, *EGFR/K-ras/ALK* “triple negative”). Interestingly, clinical activity of AUY922 was mainly observed among patients with *ALK*-positive tumors and *EGFR* mutant NSCLC, with PR confirmed in 25% of *ALK*+ patients (50% in crizotinib-naïve *ALK*+ patients), 18% in *EGFR* mutated patients, 13% in wild-type patients, and none of the *KRAS*-mutated patients. Estimated median PFS rates were 42% and 34% at 18 weeks in *ALK*-positive and *EGFR*-mutant patients, respectively. The most



common AEs were diarrhea (73%), visual disorders (71%), and nausea (43%) (63). Based on the above mentioned data, there are multiple studies underway involving patients with NSCLC receiving AUY922 either alone or in combination with other targeted agents, especially for those with either *ALK+* or *EGFR*-mutated tumors. Finally, AT13387 is another Hsp90 inhibitor which showed activity both alone and in combination with crizotinib against *ALK+* NSCLC cells lines and xenograft models (76). In the phase I, dose-escalation study including all solid tumors, the DLT observed were infusion-related symptoms, gastrointestinal effects, and fatigue. A phase I/II trial of AT13387 in NSCLC with or without crizotinib is currently ongoing.

## Conclusions

Crizotinib represents the last targeted agent approved for the treatment of NSCLC. In phase III randomized clinical trials it has shown to be superior to conventional cytotoxic agents in second line treatment of selected groups of patients with *ALK*-rearranged NSCLC. We are eagerly waiting for the results of PROFILE 1014 in the frontline setting. The clinical development of crizotinib has been an amazing success story in lung cancer translational-research. Its accelerated approval has benefited many patients whose tumors harbor this novel *EML4/ALK* translocation, marking the beginning of the new decade of targeted therapy, characterized by new ethical and scientific considerations.

Common to others targeted therapies that have revolutionized the therapy of NSCLC, such as *EGFR*-TKIs, acquired resistance to crizotinib inevitably develops during the treatment. The novel generation of *ALK* inhibitors and the Hsp90-inhibitors represent promising alternatives for those patients whose tumors develop the so called “*ALK*-dominant” mechanisms of resistance. Combination of different targeted agents may be considered to overcome the activation of alternative signaling pathways, such as *EGFR*, *KRAS*. To date, the causes of progression remain unknown in about one-third of patients receiving crizotinib. Therefore, elucidating acquired resistance mechanisms, preventing CNS progressions, and developing adequate therapeutic strategies such as the optimal sequence of treatment and the best combinations, are the crucial questions to be answered by dedicated translational research studies. Only a close collaboration between oncologists, pathologists and molecular biologists may help to find the right answers in an efficient and timely fashion.

## Acknowledgements

*Disclosure:* The authors declare no conflict of interest.

## References

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004;350:2129-39.
2. Paez JG, Jänne PA, Lee JC, et al. *EGFR* mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497-500.
3. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012;23 Suppl 7:vii56-64.
4. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming *EML4-ALK* fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561-6.
5. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, *ALK*, to a nucleolar protein gene, *NPM*, in non-Hodgkin's lymphoma. *Science* 1994;263:1281-4.
6. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat Rev Cancer* 2008;8:11-23.
7. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor *EML4-ALK*. *J Clin Oncol* 2009;27:4247-53.
8. Ouyang T, Bai RY, Bassermann F, et al. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (*NIPA*). *J Biol Chem* 2003;278:30028-36.
9. Riera L, Lasorsa E, Ambrogio C, et al. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (*NPM-ALK*)-mediated signaling and anaplastic large cell lymphoma growth. *J Biol Chem* 2010;285:26441-50.
10. Takeuchi K, Choi YL, Togashi Y, et al. *KIF5B-ALK*, a novel fusion onco-kinase identified by an immunohistochemistry-based diagnostic system for *ALK*-positive lung cancer. *Clin Cancer Res* 2009;15:3143-9.
11. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of *EML4-ALK* non-small cell lung cancer. *Eur J Cancer* 2010;46:1773-80.
12. Heuckmann JM, Balke-Want H, Malchers F, et al. Differential protein stability and *ALK* inhibitor sensitivity

- of EML4-ALK fusion variants. *Clin Cancer Res* 2012;18:4682-90.
13. Klemptner SJ, Cohen DW, Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. *J Thorac Oncol* 2011;6:1439-40.
  14. Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). *J Clin Oncol* 2011;29:abstr CRA7506.
  15. Rosell R, Sureda BM, Costa C, et al. Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURLAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (v3). *ESMO* 2012: Abstract 929.
  16. Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. *J Thorac Oncol* 2012;7:90-7.
  17. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. *Lancet Oncol* 2011;12:1004-12.
  18. Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. *J Thorac Oncol* 2011;6:905-12.
  19. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. *Clin Cancer Res* 2010;16:5581-90.
  20. Wynes MW, Sholl LM, Dietel M, et al. An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and ALK FISH and between Evaluators. *J Thorac Oncol* 2014;9:631-8.
  21. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. *J Thorac Oncol* 2011;6:459-65.
  22. Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. *Mod Pathol* 2013;26:1545-53.
  23. Sakai Y, Nakai T, Ohbayashi C, et al. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung. *Int J Surg Pathol* 2013;21:476-82.
  24. Park HS, Lee JK, Kim DW, et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. *Lung Cancer* 2012;77:288-92.
  25. Martinez P, Hernández-Losa J, Montero M, et al. Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. *PLoS One* 2013;8:e52261.
  26. Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. *J Thorac Oncol* 2013;8:45-51.
  27. Wu YC, Chang IC, Wang CL, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. *PLoS One* 2013;8:e70839.
  28. Wallander ML, Geiersbach KB, Tripp SR, et al. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. *Arch Pathol Lab Med* 2012;136:796-803.
  29. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. *Mol Cancer Ther* 2007;6:3314-22.
  30. Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. *J Clin Oncol* 2009;7:abstr 3509.
  31. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693-703.
  32. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol* 2012;13:1011-9.
  33. Kim DK, Ahn MJ, Shi Y, et al. Updated results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). *J Clin Oncol*

- 2012;30:abstr 7533.
34. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-94.
  35. Takeda M, Okamoto I, Sakai K, et al. Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression. *Clin Lung Cancer* 2012;13:157-9.
  36. Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. *Clin Cancer Res* 2012;18:4449-57.
  37. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med* 2012;18:378-81.
  38. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. *Lung Cancer* 2014;84:121-6.
  39. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol* 2012;30:863-70.
  40. Ou SH, Tan J, Yen Y, et al. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. *Expert Rev Anticancer Ther* 2012;12:447-56.
  41. Ou S, Camidge R, Engelman J, et al. Clinical activity of crizotinib in patients with advanced non-small cell lung cancer harboring ROS1 gene rearrangement. *ESMO* 2012:abstract 2091.
  42. Chen YT, Chang JW, Liu HP, et al. Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment. *J Thorac Oncol* 2011;6:2027-35.
  43. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. *J Thorac Oncol* 2011;6:942-6.
  44. Cappuzzo F, Jänne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. *Ann Oncol* 2009;20:298-304.
  45. Weickhardt AJ, Scheier B, Burke JM, et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). *J Clin Oncol* 2012;30:abstr 7526.
  46. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. *J Clin Oncol* 2011;29:e443-5.
  47. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. *Sci Transl Med* 2012;4:120ra17.
  48. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. *Clin Cancer Res* 2012;18:1472-82.
  49. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363:1734-9.
  50. Lovly CM, Heuckmann JM, de Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. *Cancer Res* 2011;71:4920-31.
  51. Azam M, Seeliger MA, Gray NS, et al. Activation of tyrosine kinases by mutation of the gatekeeper threonine. *Nat Struct Mol Biol* 2008;15:1109-18.
  52. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363:1734-9.
  53. Sun HY, FQ J. A molecular dynamics investigation on the crizotinib resistance mechanism of C1156Y mutation in ALK. *Biochem Biophys Res Commun* 2012;423:319-24.
  54. Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res* 2011;71:6051-60.
  55. Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci U S A* 2011;108:7535-40.
  56. Ou S, Govindan R, Eaton KD, et al. Phase I/II dose-finding study of crizotinib (CRIZ) in combination with erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2012;30:abstr 2610.
  57. Camidge DR, Bazhenova L, Salgia R. et al. Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. *J Thorac Oncol* 2013;8:S296. Available online: <http://journals.lww.com/jto/toc/2013/11001>
  58. Shaw AT, Camidge DR, Felip E. Results of a first-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. *Ann Oncol* 2012;23:abstr 4400.
  59. Nishio M, Kiura K, Nakagawa K. A phase I/II study of ALK inhibitor CH5424802 in patients with ALK-positive NSCLC; safety and efficacy interim results of the phase II portion. *ESMO* 2012: Abstract 4410.

60. Gadgeel S, Ou SH, Chiappori AA, et al. A Phase 1 Dose Escalation Study Of A New ALK Inhibitor, CH5424802/RO5424802, In ALK+ Non-Small Cell Lung Cancer (Nscle) Patients Who Have Failed Crizotinib (Nct01588028). *J Thorac Oncol* 2013;8:S199. Available online: <http://journals.lww.com/jto/toc/2013/11001>
61. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. *J Clin Oncol* 2010;28:4953-60.
62. El-Hariry I, Acquaviva J, Jiang Q, et al. Ganetespib: an effective strategy to overcome crizotinib resistance in ALK driven-cancers. 3rd ELCC: Abstract 251P.
63. Felip E, Carcereny E, Barlesi F, et al. Phase II activity of the HSP90 inhibitor AU922 in patients with ALK-Rearranged (ALK+) or EGFR mutated advanced non-small cell lung cancer. *Ann Oncol* 2012;23:ix152-74.
64. Matsuoka H, Kurata T, Okamoto I, et al. Clinical response to crizotinib retreatment after acquisition of drug resistance. *J Clin Oncol* 2013;31:e322-3.
65. Chmielecki J, Foo J, Oxnard GR, et al. Optimization of dosing for EGFRmutant non-small cell lung cancer with evolutionary cancer modeling. *Sci Transl Med* 2011;3:90ra59.
66. Seto T, Murakami H, Hirai F, et al. Phase i study of the ALK inhibitor LDK378 in Japanese patients with advanced, ALK rearranged NSCLC and other tumors harboring genetic ALK alterations. *J Thorac Oncol* 2013;8:S595. Available online: <http://journals.lww.com/jto/toc/2013/11001>
67. Zhang S, Wang F, Keats J, et al. AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research: 2010 Apr 17-21; Washington, DC 2010.
68. Rivera VM, Wang F, Anjum R, et al. AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. AACR 103rd Annual Meeting: AACR 2012.
69. Gettinger S, Weiss G, Salgia R, et al. A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. *Ann Oncol* 2012;23 Suppl 9:ix152-74.
70. Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. *Cancer Cell* 2011;19:679-90.
71. Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, openlabel, phase 1-2 study. *Lancet Oncol* 2013;14:590-8.
72. Ou SH, Gadgeel S, Chiappori AA, et al. Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory alk-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II study (NCT01588028). *J Thorac Oncol* 2013;8:S200. Available online: <http://journals.lww.com/jto/toc/2013/11001>
73. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? *Clin Cancer Res* 2012;18:64-76.
74. Normant E, Paez G, West KA, et al. The HSP90 Inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. *Oncogene* 2011;30:2581-6.
75. Socinski MA, Goldman J, El-Hariry I, et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced nonsmall cell lung cancer. *Clin Cancer Res* 2013;19:3068-77.
76. Smyth T, Munck J, Rodriguez-Lopez A, et al. Combining the Hsp90 inhibitor, AT13387, with crizotinib improves response in an ALK positive model of NSCLC. *J Thorac Oncol* 2013;8:S163.

**Cite this article as:** Rolfo C, Passiglia F, Castiglia M, Raez LE, Germonpre P, Gil-Bazo I, Zwaenepoel K, De Wilde A, Bronte G, Russo A, Van Meerbeeck JP, Van Schil P, Pauwels P. ALK and crizotinib: after the honeymoon...what else? Resistance mechanisms and new therapies to overcome it. *Transl Lung Cancer Res* 2014;3(4):250-261. doi: 10.3978/j.issn.2218-6751.2014.03.01